We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

11 hedge funds and large institutions have $72K invested in Viking Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

57% more funds holding

Funds holding: 7 → 11 (+4)

54% less capital invested

Capital invested by funds: $158K → $72K (-$86K)

Holders
11
Holders Change
+4
Holders Change %
+57.14%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$26.2K
2
UBS Group
UBS Group
Switzerland
+$5K
3
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
+$3.63K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.81K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.96K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$44K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$18K
3
Creative Planning
Creative Planning
Kansas
-$10K

VKTX Hedge Fund Activity: Q1 2016 in Review

11 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2016, worth a combined $72K — down 54% from $158K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VKTX positions and 3 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $26.2K. The largest seller was Goldman Sachs, exiting entirely with an estimated $44K sold.

  • 11 institutional investors held Viking Therapeutics (VKTX) as of Q1 2016, up from 7 in Q4 2015.
  • Funds reported $72K of Viking Therapeutics stock for Q1 2016, down 54% quarter-over-quarter.
  • 7 funds opened new Viking Therapeutics positions in Q1 2016 and 3 closed out, a net change of +4 holders.
  • The largest Viking Therapeutics buyer in Q1 2016 was Citadel Advisors, an estimated $26.2K added.
  • The largest Viking Therapeutics seller in Q1 2016 was Goldman Sachs, an estimated $44K sold.

Based on aggregated 13F filings for Q1 2016.